万维提示：
1、投稿方式：在线投稿。
2、期刊网址：
https://journals.lww.com/jlgtd/pages/default.aspx
3、投稿网址：
http://www.editorialmanager.com/jlgtd/mainpage.html
4、官网邮箱：editor@asccp.org（编辑部）
5、期刊刊期：季刊，逢季首月出版。
2021年7月16日星期五
投稿须知【官网信息】
Journal of Lower Genital Tract Disease
Instructions for Authors
AIMS AND SCOPE:
The JLGTD is a leading international journal dedicated to promoting prevention and treatment of anogenital and HPV-related disease. The Journal welcomes submission of original research articles focused the lower genital tract of either gender. The research focus of such articles includes, but is not limited to: treatment, prevention, diagnostic, screening, quality of life, genetic, and epidemiologic studies of the lower genital tract. We particularly welcome manuscripts pertaining to lower genital tract HPV and non-HPV related conditions, dermatologic disorders, anorectal disease, and topics relevant to underserved populations. Research pertaining to upper genital tract (uterus, fallopian tubes, ovaries) topics, maternal-fetal topics, or infertility topics without a lower genital tract focus should be directed toward alternate Journals. With respect to clinical trials, the Journal accepts only randomized, placebo-controlled trials in most instances.
Before You Begin
ETHICS IN PUBLISHING
JLGTD follows the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, issued by the International Committee of Medical Journal Editors (ICMJE Recommendations). These guidelines are included in the document entitled "Uniform Requirements for Manuscripts Submitted to Biomedical Journals," which can be found at external link http://www.icmje.org. JLGTD follows the Committee on Publication Ethics (COPE) code of conduct for editors and COPE's guidelines. JLGTD strictly adheres to standards of expected ethical behavior. These ethics apply to conduct of the research, writing of an article, and authorship.
The publication of an article in a peer-reviewed journal is an essential building block in the development of a coherent and respected network of knowledge. It is a direct reflection of the quality of work of the author and the institutions that support them. Peer-reviewed articles support and embody the scientific method.
Reporting Standards
Authors of reports of original research reports should present an accurate account of the work performed and an objective discussion of its importance. Underlying data should be represented accurately in the paper. A paper should contain sufficient detail and references to permit others to replicate the work. Fraudulent or knowingly inaccurate statements constitute unethical behavior and are unacceptable.
Originality and plagiarism
The authors should ensure they have composed entirely original works, and if the authors have used the work and/or words of others, that this has been appropriately cited or quoted. Plagiarism takes many forms, from 'passing off' another's paper as the author's own paper, to copying or paraphrasing substantial parts of another's paper (without attribution), to claiming results from research conducted by others. Plagiarism in all its forms constitutes unethical publishing behavior and is unacceptable.
Multiple, redundant or concurrent publication
An author should not, in general, publish manuscripts describing essentially the same research in more than one journal or primary publication. Submitting the same manuscript to more than one journal concurrently constitutes unethical publishing behavior and is unacceptable. Publication of some kinds of articles (e.g. clinical guidelines, translations) in more than one journal is sometimes justifiable, provided certain conditions are met. The authors and editors of the journals concerned must agree to co-publication. Further detail on acceptable forms of secondary publication can be found at www.icmje.org.
Copyright: In addition, each author must complete and submit the journal's copyright transfer agreement, which includes a section on the disclosure of potential conflicts of interest based on the recommendations of the International Committee of Medical Journal Editors, "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" (www.icmje.org/update.html).
A copy of the form is made available to the submitting author within the Editorial Manager submission process. Co-authors will automatically receive an Email with instructions on completing the form upon submission.
Examples of potential conflicts of interest, which should be disclosed, include: employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Potential conflicts of interest should be disclosed at the earliest stage possible.
All sources of financial support for the project should be disclosed. This declaration (with the heading 'Role of the funding source') should be made in a separate section of the text and placed before the References. Authors must described the role of the study sponsor(s), if any, in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.
Fundamental Errors in published works
When an author discovers a significant error or inaccuracy in his/her own published work, the author is obliged to promptly notify the journal editor or publisher and cooperate with the editor to retract or correct the report. If the editor or the publisher learns from a third party that a published work contains an error of significance, the author is obliged to promptly retract or correct the paper or provide evidence to the editor of the accuracy of the original report.
Authorship of the paper
Authorship should be limited to those making measurable contributions to the (1) the conception and design of the study, acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted. JLGTD adheres to the authorship criteria of the International Committee of Medical Journal Editors www.icjme.org. All those making significant contributions should be listed as co-authors. Where there are others who participated in certain substantive aspects of the research project, they may be acknowledged or listed as contributors.
The corresponding author should ensure that all appropriate co-authors and no inappropriate co-authors are included on the paper, and that all co-authors have seen and approved the final version of the paper and have agreed to its submission for publication. Each author must sign an authorship statement and conflict of interest statement.
Disclaimer
Statements and opinions expressed in the manuscripts are those of the author(s) and not necessarily those of the editor(s) or publisher. The editor(s) or publisher disclaim(s) any responsibility or liability for such information. The author(s), editor(s), and publisher do not guarantee, warrant, or endorse any product or service advertised in the publication, nor do they guarantee any claim made by the manufacturer of said product or service.
Animal rights
If the work involves the use of animal subjects, the author should ensure that the work described was conducted in accordance with the EU Directive 2010/63/EU for animal experiments: http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm; and with Uniform Requirements for manuscripts submitted to Biomedical journals: http://www.icmje.org
Human Rights, Informed Consent, and Patient Details
If the work involves human subjects, the author should ensure that the work described was conducted in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans: http://www.wma.net/en/30publications/10policies/b3/index.html; and Uniform Requirements for manuscripts submitted to Biomedical journals: http://www.icmje.org
Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. Studies involving live human subjects must have approval by the authors' Institutional Review Board (IRB) or its equivalent. A copy of the IRB approval letter must be included with the submission. If the IRB has exempted the research from review, a copy of the letter of exemption must accompany the submission. Please state your IRB status on the title page. If applicable, IRB approval must be mentioned in the Cover Letter and in the Methods section of the manuscript. All clinical investigations must have been conducted according to the Declaration of Helsinki principles. If the Methods section is not sufficiently clear, authors may be asked to provide the editors with a copy of IRB-approved research protocols for the use of our reviewers.
The privacy rights of human subjects must always be observed. Patients must not be identified by name or initials; numbers should be used. No other information, including clinical photos or family trees, from which a patient could be identified is permitted unless express written permission from the patient/family is provided at the time of manuscript submission. To respect your patient's and any other individual's privacy, do not send signed consent forms to JLGTD. Retain the signed form(s) in the event they should be needed.
Submissions of survey research must include: 1) A copy of the letter documenting Human Subject IRB approval. 2) A copy of the survey instrument. (The editors, in consultation with the authors, will determine if the survey instrument should be published and whether it should be published as an online-only Appendix.) The manuscript's Methods section must: 1) Attest that the use of any proprietary sampling contact information (eg, mailing list) was approved by its owner. 2) Provide IRB protocol approval number and date. 3) Describe how the survey instrument was developed and piloted, and whether/ how the survey was validated. During the review process, editors and reviewers may request a copy of the approved study protocol to aid in their evaluation of the study.
Informed Consent for Case Reports and Case Series
Appropriate consents, permissions and releases must be obtained when an author wishes to include case details or other personal information or images of patients and any other individuals. Written consents must be retained by the author and copies of the consents or evidence that such consents have been obtained must be provided to JLGTD on request. Unless written permission from the patient (or, where applicable, the next of kin) exits, the personal details of any patient included in any part of the report and in any supplementary materials (including all illustrations and videos) must be removed before submission. To respect patients' and any other individual's privacy, do not send signed consent forms to JLGTD. Retain the signed form(s) in the event they should be needed.
Undocumented claims
Please do not claim 'this is the first reported case'. If such a claim is deemed necessary, authors should explain their reasoning in the cover letter and provide a detailed Appendix describing how they came to this conclusion. Describe search strategies, search terms, databases queried, and how far back these were checked. Also list textbooks and monographs searched to substantiate the claim. Similarly, the phrase "safe and effective" should be reserved for FDA-approved product labeling based on registered phase III trials. In other settings, the term should be avoided entirely. Acceptable terminology for a case series would include the sentence "Our patients demonstrated positive responses and the treatment was well tolerated." Do not make statements that your report or references do not substantiate.
Trade names and Brand names
Trade names and brand names of drugs and devices may not be used in the titles, précis, abstract, keywords, or acknowledgements of the article. As a rule, each trade names or brand name may appear only once in the body of the text of the article (typically in the Methods) and should be placed in parentheses along with their manufacturer and the manufacturer's location following the first mention of the generic name in the text. If a brand product is named, or a trade name is used, provide: (Organization/Company. Year released. City, State, Country.) It is not necessary to use the trademark symbol. After the first mention of a trade name or brand name, only the generic name should be used throughout the article. If the author believes that the JLGTD reader would benefit from repetition of the trade name or brand name, the Editor will receive the rationale and make a judgment. Under some circumstances, use of a trade name or brand name may be permitted in each table and/or figure of an article, so that the table/figure may be understood as a standalone presentation. Use of trade names and brand names may be permitted within disclosures, conflicts of interest, role of the funding source, abbreviations, acronyms, and references.
LANGUAGE
Please write your text in proper English (American, Canadian, or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English should use English Language Editing services available to them. http://journals.lww.com/jlgtd/_layouts/1033/oaks.journals/editservices.aspx
The ASCCP is committed to upholding the highest standards of excellence in an academic community. The ASCCP is enriched by valuing diversity, which encompasses recognizing and supporting the experiences, identities, ideas and perspectives of individuals from all groups of people including those of different age, socioeconomic status, ability/disability, ethnicity, race, gender, gender identity, sexual orientation, culture, or any other identity and experience. To promote these values, the ASCCP is committed to using inclusive language that is sensitive to differences; avoids prejudice, stereotypes and discrimination; and avoids the exclusion of some individuals from being seen as part of a group. The use of inclusive language promotes respect for all people, and avoids confusion and the promotion of false ideas. ASCCP publications and presentations should be free from bias, for example, using "chair" or "chairperson" instead of "chairman." Language should include gender-inclusive descriptions of people when referring to individuals undergoing cervical cancer screening and management (for example, "people who have a cervix" rather than "women"). For further guidance on the use of inclusive language, the ASCCP recommends the following resources:
Conscious Style Guide: https://consciousstyleguide.com/about/
Center for Integration and Improvement of Journalism - Diversity Style Guide: https://www.diversitystyleguide.com/
National Center on Disability and Journalism - Disability Language Style Guide: https://ncdj.org/style-guide/
Syracuse University Disability Cultural Center Language Guide: http://sudcc.syr.edu/resources/language-guide.html
National LGBTI Health Alliance Inclusive Language Guide (Australia): http://lgbtihealth.org.au/sites/default/files/Alliance%20Health%20Information%20Sheet%20Inclusive%20Language%20Guide%20on%20Intersex,%20Trans%20and%20Gender%20Diversity_0.pdf
GLAAD Media Reference Guide: http://www.glaad.org/sites/default/files/GLAAD-Media-Reference-Guide-Tenth-Edition.pdf
Guidelines for Unbiased Language from the American Psychological Association (APA) Style manual: http://supp.apa.org/style/pubman-ch03-00.pdf
STYLE
Manuscripts must conform to acceptable English usage. Consult the latest edition of The Chicago Manual of Style by The University of Chicago Press or the Manual of Style by the American Medical Association for current usage. Abbreviations must be limited primarily to those in general usage. Weights and measurements must be expressed in metric units. Temperatures must be expressed in degrees centigrade.
Authors should write for a sophisticated general medical readership; follow principles of clear scientific writing and statistical reporting; and prepare manuscripts according to recommended reporting guidelines and checklists whenever possible. Check your submission for misspellings, proper punctuation, proper usage of word for correct meaning, proper grammar (such as verb/subject agreement), and proper English syntax (nuanced juxtaposition of words and phrases), scientific writing style, and accuracy.
ABBREVIATIONS AND ACRONYMS
Only standard abbreviations are to be used. Consult Scientific Style and Format by the Council of Biology Editors or the Manual of Style by the American Medical Association. Abbreviations in the title are not acceptable and they should be avoided in the abstract whenever possible. A laboratory or chemical term or a disease process must be spelled out at first mention, with the acronym or abbreviation following in parentheses. List all abbreviations and acronyms on a separate page within the manuscript document before the references. Do not use 'NS' within the text of the report.
BREVITY
Brevity is appreciated. Write manuscripts in the active voice. Express ideas briefly, clearly, and concisely. Avoid 'figures of speech' and 'jargon'. Take the time to condense your manuscript and express it confidently in simple, declarative sentences. Write simply and naturally, the way you speak. Authors, please note: JLGTD is contractually limited in the number of pages that can be published each month. Manuscripts should be concise and to the point. Inclusion of textbook-type material is strongly discouraged. Authors should avoid repeating the same information in the Abstract, Introduction, and Discussion. The Introduction and Discussion should pertain directly to the study being reported, and not contain a lengthy review of a disease entity or its treatment.
Article Guidelines
GENERAL OVERVIEW
The Journal of Lower Genital Tract Disease will publish (1) original articles in basic science and clinical practice, (2) correspondence, (3) invited editorial commentary, (4) review articles, (5) case reports, (6) book reviews, (7) abstracts from relevant meetings, (8) descriptions of technique/technology, and (9) a separate section dealing with vulva and vagina.
TYPES OF ARTICLES
Original Research
The JLGTD will publish original articles in basic science and clinical practice within the defined scope, described above.
RANDOMIZED CONTROLLED TRIALS
Authors of randomized control trials (RCT) must follow the guidelines presented in the CONSORT statement (http://www.consort-statement.org/)1,2, and submit a completed CONSORT manuscript checklist with their manuscript. Any reports of clinical trials must be registered by the time of submission. The word "random" or "randomized" should be in the title. The method of randomization, and allocation concealment must be specifically stated. Randomized trials must be submitted in a format consistent with the CONSORT statement, and include a CONSORT flow diagram as a figure (http://www.consort-statement.org/statement/figure1.htm). For reporting of harms and adverse outcomes, the extension of the CONSORT statement should be used and provided.3 For Cluster RCT, use (http://www.consort-statement.org/extensions?ContentWidgetId=554).4 For noninferiority and equivalence RCT, use the CONSORT Statement extension.5 For nonpharmacologic RCT, use the CONSORT extension.6 For herbal intervention RCT, use the CONSORT statement elaboration.7
COHORT, CASE-CONTROL, AND CROSS-SECTIONAL STUDIES
Authors of reports of cohort, case-control, and cross-sectional studies of the prevalence, causes, mechanisms, diagnosis, course and prognosis, treatment, and prevention of disease (observational studies) must follow the guidelines presented in the STROBE statement (http://www.strobe-statement.org/Checklist.html), and submit a completed STROBE manuscript checklist for cohort, case-control, and cross-sectional studies with their manuscript.9,10 For reports of Molecular Epidemiology, use the STROBE-ME extension for Molecular Epidemiology.11 For reports of Genetic Risk Prediction, use the GRIPS Statement for Genetic Risk Prediction Studies.12 Genetic association studies must be reported according to STREGA guidelines. We encourage the registration of all observational studies on a WHO-compliant registry (see Lancet 2010; 375: 348).
COST-EFFECTIVENESS STUDIES
Authors of cost-effectiveness studies must follow the guidelines presented in the CHEERS statement and checklist.13 (http://www.equator-network.org/wp-content/uploads/2013/09/CHEERS-Checklist-PDF.pdf)
STUDIES OF DIAGNOSTIC ACCURACY
Authors of studies of diagnostic accuracy must follow the guidelines presented in the in the STARD guideline statement (http://www.stard-statement.org/), and include a STARD flow diagram.14 (http://www.equator-network.org).
DECISION AIDS
Authors of decision aids must follow the International Patient Decision Aid Standards (IPDAS) and OHRI conceptual framework (Ottawa Decision Support Framework (ODSF)). (https://decisionaid.ohri.ca/methods.html)
GUIDELINES
Authors of guidelines are advised to follow the Appraisal of Guidelines for Research and Evaluation (AGREE II) Instrument for the process of practice guideline development and the quality of reporting. Systematic methods must be used to search for evidence. The inclusion and exclusion criteria for selecting the evidence must be clearly described. The strengths and limitations of the body of evidence must be clearly described. The health benefits, side effects, and risks must be considered in formulating the recommendations. The recommendations must be specific and unambiguous. There must be an explicit link between the recommendations and the supporting evidence. The methods for grading evidence and for the strength of recommendations must be clearly described. Acceptable sources of previously published methodology for evidence-based statements and recommendations include GRADE and USPSTF. (http://www.gradeworkinggroup.org)
Systematic Review, Meta-Analysis, Narrative Review
Systematic reviews and meta-analyses must be reported according to PRISMA guidelines (http://prisma-statement.org). The manuscript must include a description of how authors searched for all the evidence, how they assessed the quality of that evidence, and how they combined the evidence. Assess risk of bias for trials, but avoid using summary quality scales and scores.8 A PRISMA checklist and flow diagram must be provided (http://www.equator-network.org). For meta-analyses of randomized, controlled trials, follow MOOSE reporting guidelines and provide the checklist (http://consort-statement.org/initiatives/moose/moosecheck.pdf).
A narrative review article is expected to be comprehensive, scholarly, and balanced, presenting an expert critical appraisal of the literature on the topic of interest. A current review of a disease or treatment may be considered. A systematic review is preferred. The author must explain in the cover letter that a literature search identified no published systematic review on the topic, and provide reasons why a systematic review was not appropriate for this manuscript. 6 figures or tables; not to exceed 7 printed journal pages. Reference number is limited to the number of studies included in the systematic review plus an additional 12.
Case Report
Case reports are rarely appropriate for JLGTD, unless they provide new insights and teach something important and true. An example of a case report that merited publication: Barnard CN. The operation: A human cardiac transplantation. An interim report of the successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J 1967;41:1271. All accepted case reports will only be published online. Authors of case reports must follow the guidelines presented in the CARE guidelines. 15,16
Case Series
Case series may be published in print or online-only, at the discretion of the Editor.
Similar to Case Reports, Case Series are only acceptable when they provide new insights and teach something important and true. In many instances, authors should consider using the Case Series as the basis for submission of a Narrative Review.
Letter to the Editor
Letters commenting on material previously published in JLGTD will be considered. Letters should not have an abstract. Letters will be sent for response to the authors of the article being commented upon. This response may be published or sent directly to the commentator at the discretion of the editor. All Letters to the Editor are subject to editing and possible abridgment.
Example of a great Letter to the Editor, expressed in 119 words: McBride,WG. Thalidomide and Congenital Abnormalities. Letter to the Editor. The Lancet 1961;2:1358 http://www.jameslindlibrary.org/illustrating/records/thalidomide-and-congenital-abnormalities/whole_articles
Questions or comments that could be addressed directly by the authors (including complaints about missed citations) should be sent directly to them, rather than involving JLGTD as an intermediary.
Commentary
Brief, provocative, opinionated communications, not necessarily documented, on a limited subject. Pairs of commentary that take contrary views on unsettled questions of diagnosis and treatment, particularly questions arising on common, important clinical problems may be accepted. A brief publication about a pilot study or a new diagnostic technique may be considered. Commentary may be published in print or online-only, at the discretion of the Editor. Good examples include: Call to Action, Safety Concern.
Tribute, In Memoriam
A tribute to a departed colleague who has contributed significantly to the fields of lower genital health and disease. In Memoriam submissions are limited to 400 words and are designated for online-only publication.
Editorial
Editorials are the voice of JLGTD and are written in-house by the journal's Editor-in-Chief or Senior Editors and are signed by the Editor(s).
……
更多详情：
http://edmgr.ovid.com/jlgtd/accounts/ifauth.htm
